ROSUVASTATIN SANDOZ rosuvastatin (as calcium) 5 mg film-coated tablets blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

rosuvastatin sandoz rosuvastatin (as calcium) 5 mg film-coated tablets blister pack

sandoz pty ltd - rosuvastatin calcium, quantity: 5.198 mg - tablet, film coated - excipient ingredients: hypromellose; maize starch; sodium stearylfumarate; colloidal anhydrous silica; silicon dioxide; mannitol; lactose; microcrystalline cellulose; purified talc; macrogol 6000; titanium dioxide; iron oxide yellow; iron oxide red - rosuvastatin sandoz should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin sandoz is indicated for prevention of major cardiovascular events in men greater than equal to 50 years old and women greater than equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease).,rosuvastatin sandoz is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin sandoz is indicated for the treatment of hypercholesterolaemia (excluding heterozygous familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin sandoz, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

ROSUVASTATIN PCOR rosuvastatin (as calcium) 20 mg film-coated tablet bottle pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

rosuvastatin pcor rosuvastatin (as calcium) 20 mg film-coated tablet bottle pack

pharmacor pty ltd - rosuvastatin calcium, quantity: 20.8 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium oxide; purified water; lactose monohydrate; magnesium stearate; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide red - rosuvastatin pcor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events rosuvastatin pcor is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin pcor is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin pcor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with rosuvastatin pcor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

ROSUVASTATIN PCOR rosuvastatin (as calcium) 10 mg film-coated tablet bottle pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

rosuvastatin pcor rosuvastatin (as calcium) 10 mg film-coated tablet bottle pack

pharmacor pty ltd - rosuvastatin calcium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; crospovidone; purified water; lactose monohydrate; magnesium oxide; titanium dioxide; hypromellose; triacetin; iron oxide red - rosuvastatin pcor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events rosuvastatin pcor is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin pcor is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin pcor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with rosuvastatin pcor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

ROSUVASTATIN PCOR rosuvastatin (as calcium) 10 mg film-coated tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

rosuvastatin pcor rosuvastatin (as calcium) 10 mg film-coated tablet blister pack

pharmacor pty ltd - rosuvastatin calcium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: magnesium stearate; purified water; microcrystalline cellulose; magnesium oxide; crospovidone; lactose monohydrate; titanium dioxide; hypromellose; triacetin; iron oxide red - rosuvastatin pcor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events rosuvastatin pcor is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin pcor is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin pcor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with rosuvastatin pcor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

ROSUVASTATIN PCOR rosuvastatin (as calcium) 40 mg film-coated tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

rosuvastatin pcor rosuvastatin (as calcium) 40 mg film-coated tablet blister pack

pharmacor pty ltd - rosuvastatin calcium, quantity: 41.6 mg - tablet, film coated - excipient ingredients: magnesium oxide; magnesium stearate; lactose monohydrate; microcrystalline cellulose; purified water; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide red - rosuvastatin pcor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events rosuvastatin pcor is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin pcor is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin pcor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with rosuvastatin pcor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

ROSUVASTATIN PCOR rosuvastatin (as calcium) 20 mg film-coated tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

rosuvastatin pcor rosuvastatin (as calcium) 20 mg film-coated tablet blister pack

pharmacor pty ltd - rosuvastatin calcium, quantity: 20.8 mg - tablet, film coated - excipient ingredients: magnesium stearate; magnesium oxide; lactose monohydrate; crospovidone; microcrystalline cellulose; purified water; titanium dioxide; hypromellose; triacetin; iron oxide red - rosuvastatin pcor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events rosuvastatin pcor is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin pcor is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin pcor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with rosuvastatin pcor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

APO-OLMESARTAN/AMLODIPINE/HCTZ 40/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/12.5 mg film-coated tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 40/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/12.5 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 6.95 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; pregelatinised maize starch; magnesium stearate; povidone; lactose monohydrate; silicified microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/5/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

APO-OLMESARTAN/AMLODIPINE/HCTZ 40/5/25 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/25 mg film-coated tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 40/5/25 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/25 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: povidone; pregelatinised maize starch; silicified microcrystalline cellulose; lactose monohydrate; magnesium stearate; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/5/25 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

APO-OLMESARTAN/AMLODIPINE/HCTZ 40/10/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/12.5 mg film-coated tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 40/10/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/12.5 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.9 mg; hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/10/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

APO-OLMESARTAN/AMLODIPINE/HCTZ 20/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg film-coated tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 20/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; magnesium stearate; lactose monohydrate; povidone; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - apo-olmesartan/amlodipine/hctz 20/5/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.